Skip to main content
Erschienen in: Respiratory Research 1/2020

Open Access 01.12.2020 | Research

Computed tomography patterns predict clinical course of idiopathic pulmonary fibrosis

verfasst von: Byoung Soo Kwon, Jooae Choe, Kyung Hyun Do, Hee Sang Hwang, Eun Jin Chae, Jin Woo Song

Erschienen in: Respiratory Research | Ausgabe 1/2020

Abstract

Background

A new clinical guideline for idiopathic pulmonary fibrosis (IPF) uses high-resolution computed tomography (HRCT) patterns for diagnostic purposes. However, it is unknown how they relate to the IPF clinical course. We aimed to investigate whether HRCT patterns could be used to predict lung function changes and survival in patients with IPF.

Methods

Clinical data were retrospectively reviewed in 337 patients with IPF (all biopsy-proven cases). HRCT patterns were classified according to the 2018 IPF diagnostic criteria.

Results

The median follow-up was 46.9 months. The mean age was 62.5 years, and 74.2% were men. Among the HRCT patterns, usual interstitial pneumonia (UIP), probable UIP, indeterminate for UIP, and an alternative diagnosis were identified in 163 (48.4%), 110 (32.6%), 33 (9.8%), and 31 (9.2%) patients, respectively. The indeterminate for UIP group showed higher lung function and exercise capacity and better prognosis than the other groups. They also had a lesser decline in lung function than the other groups during follow-up. In the multivariate Cox analysis, which was adjusted by age, smoking status, lung function, exercise capacity, and use of antifibrotic agents, indeterminate for UIP pattern was found to be an independent prognostic factor (hazard ratio 0.559, 95% confidence interval 0.335–0.933, P = 0.026). However, the probable UIP group had similar lung function changes and prognosis when compared the UIP group.

Conclusions

Our results suggest that indeterminate for UIP pattern on HRCT may predict a more favorable clinical course in patients with IPF, supporting the validity of the new IPF diagnostic guidelines.
Hinweise
Byoung Soo Kwon and Jooae Choe equally contributed to this work as first authors
Eun Jin Chae and Jin Woo Song contributed to this work as corresponding authors

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12931-020-01562-2.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
DLCO
Diffusing capacity of the lung for carbon monoxide
FVC
Forced vital capacity
HRCT
High-resolution computed tomography
IPF
Idiopathic pulmonary fibrosis
PFT
Pulmonary function test
TLC
Total lung capacity
UIP
Usual interstitial pneumonia
6MWT
Six-minute walk test

Introduction

Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia. It has the worst prognosis with a median survival time of 3 years [1]. The clinical course of IPF is variable [2], and predicting its prognosis is difficult. Previous studies have reported that baseline and change in lung function over time and exercise capacity are associated with poor prognosis in IPF [35]. Although high-resolution computed tomography (HRCT) is a pivotal modality for diagnosing IPF, it is unclear if it can be used for predicting the clinical course of IPF; previous studies on the association between HRCT patterns and survival, based on the 2011 IPF diagnostic criteria, showed inconsistent results [6, 7]. Salisbury et al. reported that biopsy-proven IPF patients with a possible usual interstitial pneumonia (UIP) pattern on HRCT had significantly prolonged survival than those with a definite UIP pattern in multivariate Cox analysis adjusted by age, gender, smoking status, pulmonary function, and fibrosis extent [6]. In contrast, Acardu et al. conducted a retrospective analysis of 350 patients with IPF and reported that a consistent UIP pattern was not associated with poorer survival than a possible or inconsistent pattern on HRCT when adjusted by age, sex, and lung function [7]. These contradictory findings may be due to differences in baseline demographic features and disease severity between studies. Therefore, the usefulness of HRCT in predicting clinical course of IPF is still unknown.
In 2018, a new clinical guideline for IPF was released, which reclassified the HRCT patterns into four categories: UIP, probable UIP, indeterminate for UIP, and alternative diagnosis [8]. The most important change from the previous guideline was that possible UIP pattern based on the 2011 guideline was subdivided into probable UIP and indeterminate for UIP [9]. Therefore, it can be assumed that a more detailed HRCT classification may be more useful in predicting the clinical course of IPF. However, it is unclear whether these newly defined HRCT patterns can be used to predict the clinical course of IPF. Therefore, the aim of this study was to evaluate the impact of HRCT patterns on clinical course including lung function changes and survival in patients with IPF.

Material and methods

Study population

Between July 1995 and January 2016, 534 patients who underwent a surgical lung biopsy for diagnosing fibrosing interstitial lung disease were identified from the Asan Medical Centre, Seoul, South Korea. Among them, 196 patients were excluded due to other diagnoses, and one patient was excluded because of unavailability of HRCT images. Finally, 337 patients were included in this study (Fig. 1). All patients met the IPF diagnostic criteria of the 2018 American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society, and Latin American Thoracic Society statement. The diagnoses were confirmed through a multidisciplinary discussion. This study was approved by the Institutional Review Board of Asan Medical Centre (2018–1284), and informed consent was waived due to the retrospective nature of the study.

Data collection

Clinical and survival data for all patients were retrospectively obtained from medical records, telephonic interviews, and/or the records of the National Health Insurance of Korea. The pulmonary function test results, forced vital capacity (FVC), total lung capacity (TLC), and diffusing capacity of the lung for carbon monoxide (DLCO) were measured based on the ATS/ERS recommendations [1012]. The results are expressed as percentages of the normal predicted values. The six-minute walk test (6MWT) was performed according to the ERS/ATS recommendations [13].
Data from the follow-up visits (conducted every 3–6 months) or hospitalizations were reviewed to determine the development of complications, such as pneumonia, acute exacerbation (AE), lung cancer, and pneumothorax. AE was defined according to the criteria suggested by Collard et al. [14]

HRCT evaluation

HRCT scans were obtained in accordance with standard protocols at full inspiration without contrast enhancement. The HRCT images acquired at the time of diagnosis were independently reviewed by three thoracic radiologists (JC, KHD, and EJC) blinded to the clinical and pathologic information. Overall, the HRCT pattern was categorized as UIP, probable UIP, indeterminate for UIP, and an alternative diagnosis, based on the IPF diagnostic criteria [8]. The UIP pattern was defined as subpleural, basal predominance of reticular abnormalities, honeycombing with or without traction bronchiectasis, and the absence of findings inconsistent with a UIP pattern including extensive ground-glass opacity, micronodules, discrete cysts, mosaic attenuation, or segmental/lobar consolidation [8]. Representative radiologic images of each HRCT pattern are shown in Additional file 1. Disagreement between the three readers was resolved via a consensus.

Statistical analysis

All values are expressed as a mean ± standard deviation for continuous variables or as percentages for categorical variables. The Student’s t-test or the Mann–Whitney U test was used for continuous data, and Pearson’s chi-squared test or Fisher’s exact test was used for categorical data. The generalized interobserver agreement for all three readers was evaluated using Fleiss’ κ and an intraclass correlation coefficient (ICC). The strength of agreement was as follows: κ < 0.04 = poor agreement, 0.4–0.75 = good agreement, and κ > 0.75 = excellent agreement [15]. Survival was evaluated by the Kaplan–Meier survival analysis and the log-rank test. To estimate the survival time, we defined events as any cause of death or lung transplantation. The Cox regression model was used to identify the prognostic factors for survival. Variables with a P-value of < 0.1 in the univariate analysis were entered into the multivariate models (backward log-likelihood ratio statistics method). Lung function decline was estimated using a mixed-effect model with a random intercept and random slope, adjusting for age, sex, smoking history, and HRCT patterns as fixed effects and time as a random effect. All P-values were two-tailed. A P-value of < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22 (SPSS Inc., Armonk, NY, USA).

Results

Baseline characteristics

The median follow-up period was 46.9 months (interquartile range: 22.8–78.2 months). The mean age of the patients was 62.5 years; 74.2% were men, and 68.8% were ever-smokers. Among the HRCT patterns, the UIP pattern was the most common (48.4%), followed by the probable UIP pattern (32.6%), indeterminate for UIP pattern (9.8%), and alternative diagnosis (9.2%) (Fig. 1). The most common findings in the alternative diagnosis group were predominant ground-glass opacity, peribronchovascular distribution, and upper or mid-lung distribution (an additional file shows this in more detail [see Additional file 1: Table S1]). Interobserver agreement across the HRCT patterns showed moderate reliability (κ = 0.50, range 0.49–0.62; ICC = 0.81). Interobserver agreement according to the HRCT patterns was the highest in UIP pattern (κ = 0.62), followed by indeterminate for UIP pattern (κ = 0.47), probable UIP pattern (κ = 0.44), and alternative diagnosis (κ = 0.36).
There were significant differences in sex, smoking status, baseline lung function, and a saturation of oxygen during the 6MWT across four groups (Table 1). Patients with indeterminate for UIP pattern were more likely to be men and ever-smokers and had higher lung function (FVC, DLco, TLC) and oxygen saturation (initial and the lowest) during the 6MWT than the other groups. However, the 6MWT distance, baseline bronchoalveolar lavage fluid findings, and treatment during follow-up were not different among the four groups (Table 1).
Table 1
Comparison of the baseline characteristics in patients with IPF according to the HRCT patterns
 
UIP
Probable
Indeterminate
Alternative
P-value
No. of patients
163
110
33
31
 
Age, years
61.9 ± 7.6
62.9 ± 7.3
63.0 ± 7.7
63.5 ± 7.8
0.550
Male
133 (81.6)
71 (64.5)
29 (87.9)
17 (54.8)
 < 0.001
Ever-smokers
126 (77.3)
66 (60.0)
28 (84.8)
12 (38.7)
0.001
PFT, % predicted (n = 336)
n = 163
n = 110
n = 33
n = 30
 
 FVC
69.9 ± 18.5
73.7 ± 14.9
84.6 ± 13.6
66.7 ± 18.5
 < 0.001
 DLCO
57.6 ± 17.2
66.5 ± 17.0
70.2 ± 21.1
58.4 ± 13.5
 < 0.001
 TLC
69.7 ± 15.1
73.1 ± 13.3
83.5 ± 11.4
69.3 ± 15.3
 < 0.001
6MWT (n = 324)
n = 157
n = 107
n = 32
n = 28
 
 Distance, meter
448.2 ± 110.7
459.5 ± 95.4
475.3 ± 92.2
440.6 ± 110.5
0.461
 Initial SpO2, %
96.0 ± 1.8
96.5 ± 1.3
97.3 ± 1.1
96.3 ± 1.7
 < 0.001
 Lowest SpO2, %
89.5 ± 6.0
92.2 ± 4.5
93.5 ± 5.0
89.7 ± 6.2
 < 0.001
BAL fluid analysis (n = 220)
n = 118
n = 72
n = 15
n = 15
 
 WBC, /μl
289.2 ± 278.4
305.0 ± 237.2
354.7 ± 305.5
233.5 ± 171.0
0.622
 Neutrophil, %
12.0 ± 20.2
8.6 ± 15.3
6.5 ± 5.5
12.9 ± 18.8
0.438
 Lymphocyte, %
13.2 ± 12.6
12.0 ± 10.4
15.9 ± 15.9
15.7 ± 13.9
0.570
Treatment
 Antifibrotic agents
56 (34.6)
46 (42.2)
12 (36.4)
5 (16.7)
0.258
 Steroid ± IM
63 (38.9)
38 (34.9)
8 (24.2)
16 (53.3)
0.737
 No treatment
43 (26.5)
25 (22.9)
13 (39.4)
9 (30.0)
0.392
Data are expressed as a mean ± standard deviation or a number (%) unless otherwise indicated
IPF, idiopathic pulmonary fibrosis; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia; PFT, pulmonary function test; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; 6MWT, six-minute walk test; SpO2, saturation of peripheral oxygen; BAL, bronchoalveolar lavage; WBC, white blood cell; IM, immunosuppressant
There was a statistically significant difference compared to indeterminate for UIP (P < 0.05)

Lung function changes and complications

The indeterminate for UIP group displayed a significantly lesser decline rate of FVC (− 1.57% predicted/year) than the other groups (− 3.50% predicted/year in the UIP group, P < 0.001; − 2.79% predicted/year in the probable UIP group, P < 0.001; − 2.64% predicted/year in the alternative diagnosis group, P = 0.001) (Fig. 2a, an additional file shows this in more detail [see Additional file 1: Table S2]). In addition, the indeterminate for UIP group had a lesser decline rate of DLco (− 1.86% predicted/year) than the other groups (− 5.0% predicted/year in the UIP group, P < 0.001; − 3.98% predicted/year in the probable UIP group, P < 0.001) (Fig. 2b, an additional file shows this in more detail [see Additional file 1: Table S2]). Change in the TLC of the indeterminate UIP group (− 1.90% predicted/year) showed a lesser decline rate than that of the UIP (− 3.33% predicted/year in UIP, P < 0.001), probable UIP (− 2.57% predicted/year, P < 0.001), or alternative diagnosis group (− 2.38% predicted/year, P = 0.005) (Fig. 2c, an additional file shows this in more detail [see Additional file 1: Table S2]). During the follow-up period, a total of 137 (40.7%) patients were admitted to hospital due to complications. AE (56.9%) was the most common cause of hospital admission. There were no differences in the development of complications across the four groups. However, the indeterminate for UIP group showed a tendency of longer AE free survival period and a higher frequency of lung cancer than the other groups (Table 2).
Table 2
Comparison of the complications in patients with IPF according to the HRCT patterns
 
UIP
Probable
Indeterminate
Alternative
P-value
No. of patients
163
110
33
31
 
Unexpected respiratory hospitalization
66 (42.9)
49 (40.9)
9 (27.3)
13 (41.9)
0.393
 Acute exacerbation
36 (22.1)
32 (29.1)
4 (12.1)
6 (19.4)
0.564
 Time interval from diagnosis, months
36.7 ± 42.2
46.6 ± 39.8
92.9 ± 67.5
47.5 ± 26.2
0.089
 Pneumonia
24 (14.7)
17 (15.5)
3 (9.1)
5 (16.1)
0.857
 Pneumothorax
6 (3.7)
0 (0.0)
2 (6.1)
2 (6.5)
0.497
Lung cancer
24 (14.7)
8 (7.3)
5 (15.2)
1 (3.2)
0.092
Data are expressed as a mean ± standard deviation or as a number (%)
IPF, idiopathic pulmonary fibrosis; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia
There was a statistically significant difference compared to indeterminate for UIP (P < 0.05)

Survival and prognostic factors

During follow-up, 70.0% of the total patients died, and 3.3% of patients underwent a lung transplantation. The median survival time of all subjects was 57.2 months. The indeterminate for UIP group displayed better survival (median survival period: 130.3 months) than the other groups (43.5 months in the UIP group, P < 0.001; 61.2 months in the probable UIP group, P = 0.005; 52.1 months in the alternative diagnosis group, P = 0.003) (Fig. 3).
In the univariate Cox analysis, probable UIP pattern and indeterminate for UIP pattern on the HRCT were significant predicting factors for survival in IPF patients along with younger age, ever-smoker, higher FVC, TLC, and DLCO, longer 6MWT distances, higher baseline, and the lowest oxygen saturation during the 6MWT, and anti-fibrotic treatment (Table 3). In the multivariate analysis, an indeterminate for UIP pattern on the HRCT was also an independent prognostic factor (hazard ratio [HR] 0.559, 95% confidence interval [CI] 0.335 – 0.933, P = 0.026) in IPF patients along with an alternative diagnosis pattern, younger age, higher FVC, longer walking distance and higher nadir oxygen saturation during the 6MWT, and antifibrotic treatment (Table 3).
Table 3
Prognostic factors for the mortality in patients with IPF assessed using Cox’s proportional hazards model
 
Univariate
Multivariate
Hazard ratio (95% CI)
P-value
Hazard ratio (95% CI)
P-value
Age
1.035 (1.016–1.054)
< 0.001
1.042 (1.021–1.064)
< 0.001
Male
0.879 (0.647–1.196)
0.413
  
Ever-smokers
0.727 (0.554–0.954)
0.021
  
FVC
0.963 (0.955–0.972)
< 0.001
0.974 (0.963–0.985)
< 0.001
DLCO
0.968 (0.960–0.976)
< 0.001
  
TLC
0.957 (0.947–0.967)
< 0.001
  
6MWT, distance
0.996 (0.994–0.997)
< 0.001
0.998 (0.997–1.000)
0.049
6MWT, initial SpO2
0.794 (0.734–0.859)
< 0.001
  
6MWT, lowest SpO2
0.910 (0.893–0.922)
< 0.001
0.948 (0.923–0.974)
< 0.001
Antifibrotic agents
0.392 (0.290–0.530)
< 0.001
0.446 (0.324–0.615)
< 0.001
HRCT pattern
 
< 0.001
 
0.002
 UIP
1
 
1
 
 Probable UIP
0.598 (0.446–0.802)
0.001
0.781 (0.565–1.078)
0.132
 Indeterminate
0.299 (0.179–0.499)
< 0.001
0.431 (0.254–0.732)
0.002
 Alternative
0.725 (0.467–1.124)
0.150
0.520 (0.318–0.849)
0.009
IPF, idiopathic pulmonary fibrosis; CI, confidence interval; PFT, pulmonary function test; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; 6MWT, six-minute walk test; SpO2, saturation of peripheral oxygen; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia
TLC was excluded from the multivariate analysis due to its close correlation with FVC

Discussion

In this study, IPF patients with an indeterminate for UIP pattern, which was a newly defined category in the revised IPF diagnostic criteria, exhibited more preserved lung function and a better clinical course (lesser decline in lung function and higher survival rate) than those with other HRCT patterns. Even when adjusted by clinical variables, including the baseline lung function and antifibrotic treatment, an indeterminate for UIP pattern independently predicted better survival. Conversely, IPF patients with probable UIP pattern had similar prognosis when compared with those with UIP pattern.
Chung and colleagues, in 201 patients with pulmonary fibrosis who had lung tissue samples taken, suggested that the possible UIP pattern could be subdivided into probable and indeterminate for UIP [16]. Indeterminate for UIP is defined as having subtle reticulation or ground-glass opacity on HRCT that is not classifiable into the other categories [8]. They demonstrated that histologic UIP was proven in 82.4% of patients with probable UIP on HRCT and 54.2% of patients with indeterminate UIP (P = 0.01). In our study using biopsy-proven IPF patients, the indeterminate for UIP group had a better prognosis than the other groups. These findings implicated that the HRCT patterns may predict different clinical courses, as well as histologic correlation. Although it might be thought that a favorable prognosis is related to an early diagnosis, the findings of our study, in which the indeterminate for UIP group has been identified as an independent prognostic factor even when adjusted by age, lung function, exercise capacity, and antifibrotic treatment, suggest that the clinical course of the indeterminate group might be different from that of the other groups.
In our study, there were no significant differences in survival between IPF patients with the UIP pattern on HRCT and those with the probable UIP pattern. To date, inconsistent results regarding the association between survival and HRCT patterns were shown [6, 7, 17]. Arcadu et al. in 350 patients with IPF (197 biopsy-proven cases), showed no significant difference in survival between patients with a UIP pattern and those with a non UIP pattern (possible and/or inconsistent UIP pattern; HR 1.29, 95% CI 0.90–1.83, P = 0.15) on HRCT [7]. Lee et al. in 606 patients with IIP whose HRCT pattern was UIP (n = 544) or possible UIP (n = 62), showed that a 3-year survival rate was different according to the HRCT patterns (44.6% in the UIP group vs. 56.8% in the possible UIP group, P = 0.04). However, a propensity matching analysis of 122 patients (61 in the UIP group and 61 in the possible UIP group) showed that there was no survival difference between the two groups (48.7% vs. 61.1%, P = 0.17) [17]. In contrast, Salisbury et al. in 133 patients with biopsy-proven IPF, reported that patients with a definite UIP pattern on HRCT (n = 41) had a shorter survival period than those with a possible UIP pattern (median survival period: 2.27 vs. 6.95 years, P = 0.002) [6]. These conflicting results may be due to heterogeneous populations (various diagnoses and disease severity) in each study. Recently, Fukihara et al. in 311 IPF patients with HRCT pattern of UIP (n = 154) or probable UIP (n = 157), reported that the HRCT patterns were not significantly associated with survival in the multivariate analysis adjusted by age, sex, FVC, DLCO, and use of antifibrotic agents (HR 0.883, 95% CI 0.640–1.218, P = 0.447) [18]. They categorized the HRCT patterns according to the revised diagnostic criteria, and showed consistent results with our findings. Therefore, insignificant survival differences between patients with UIP and probable UIP pattern on HRCT may advocate the current guidelines, in which surgical lung biopsy is conditionally recommended in the probable UIP pattern [8, 19].
There were significant differences in lung function decline in IPF patients according to the HRCT patterns in our study. Although lung function changes were not significant between the UIP and the probable UIP group, lesser lung function changes were notable in the indeterminate for UIP group. Similarly, Raghu et al. in a post hoc subgroup analysis from the INPULSIS trial, reported that among the placebo group, the rate of lung function decline in patients who had a possible UIP pattern with traction bronchiectasis on HRCT was comparable to that in patients with a UIP pattern on a surgical lung biopsy or HRCT (− 221.0 vs. − 225.7 ml/year) [20]. However, any other data have not existed on the trajectory of lung function according to each HRCT pattern. Instead, studies on the association between lung function changes and disease severity stratified into baseline FVC were reported [21, 22]. Helen et al. in 416 patients with IPF, showed that the annual decline in FVC was not different (− 4.6% predicted/year vs. − 4.9% predicted/year, P = 0.779) between patients with FVC ≥ 80% predicted and those with FVC < 80% predicted [21]. Furthermore, Kolb et al. using the placebo group from the INPULSIS trial, showed that the rate of decline in FVC per year in IPF patients with baseline FVC ≥ 90% predicted was similar to that in those with FVC < 90% predicted (− 224.6 ml/year vs. − 223.6 ml/year) [22]. Considering that patients with an indeterminate for UIP pattern showed better lung function (mean FVC ≥ 80% predicted) than the other groups, our results were inconsistent with previous findings. These contradictory findings may be due to differences in treatment status of the study population (no treatment [22] or a small number of patients receiving antifibrotic agents [21]). Recently, Cocconcelli et al. in 49 patients with IPF naïve of antifibrotic agents, showed that changes in alveolar score, defined as extent of ground-glass opacities, were associated with FVC decline (r = 0.66, P = 0.002) [23]. Although our study did not use a quantitative scoring system, our results suggest that along with quantitative measure and lung function, qualitative evaluation of HRCT at baseline could be a useful predicting prognosis.
In the current study, lung cancer tended to be more likely to be developed in patients with a UIP pattern on HRCT in addition to those with indeterminate for UIP pattern. However, previous study showed results inconsistent with our findings; Almeida et al. in 244 patients with ILD, reported that there were no significant differences in the lung cancer incidence according to the HRCT pattern (8.5% in UIP, 10.5% in probable UIP, and 16.7% in indeterminate UIP, P = 0.551) [24]. However, of the all subjects, only 38.4% had IPF and 29.1% was ever-smokers. In patients with IPF, an exceedingly high proportion of carcinomas, including squamous carcinomas, develop at the same sites where fibrosis and tissue remodelling are predominant (peripheral and/or basal lung areas), and are topographically associated with honeycomb lesions and epithelial metaplasia [25, 26]. Calio et al. also demonstrated that the immunohistochemical characterization of lung cancer in IPF patients exhibited more varying bronchiole-related markers than that in non-IPF patients, [27] suggesting that lung cancer in IPF arise from transformed small airways in honeycomb lung areas where abnormal bronchiolar proliferation takes place. These results support our finding showing higher incidences of lung cancer in IPF patients with an UIP pattern on HRCT.
This study has several limitations. First, this study was conducted in a single centre and had a retrospective design. However, the baseline characteristics of our patients were similar to those of previous studies [6, 17, 20]. Second, our study only included IPF patients confirmed by surgical lung biopsy. As surgical lung biopsies cannot be done in patients that have a high risk of postoperative complications, the included subjects may have better-preserved lung function. Nevertheless, when lung function was adjusted in the multivariate Cox analysis, the HRCT pattern was still a significant predicting factor for survival in patients with IPF. Third, the number of patients with indeterminate for UIP pattern or alternative diagnosis, compared to that with UIP or probable UIP pattern on HRCT, was small. Previous studies reported that 35–60% of interstitial lung disease patients with a pathologic UIP pattern showed an inconsistent UIP pattern on HRCT [16, 28]. However, the current study included only those diagnosed with IPF through a surgical lung biopsy, excluding nonspecific interstitial pneumonia or chronic hypersensitivity pneumonitis. Even considering a small number of subjects, our results suggest the usefulness of HRCT in predicting survival in patients with IPF. Finally, interobserver agreement for HRCT patterns was not high. However, interobserver agreement in our study is comparable to that of previous study (kappa value 0.66–0.69) [29]. A recent study of 98 patients with ILD showed that the new software, IPFdatabase, can improve interobserver agreement among radiologists (kappa value of 0.18 to 0.64) [30]. Further studies on enhancing the interobserver agreement are warranted.
In conclusion, an indeterminate for UIP pattern on HRCT was associated with more stable lung function changes and better survival in patients with IPF. These results suggest that HRCT may be useful in classifying subgroups with a better prognosis among patients with IPF. This supports the validity of the new classification guidelines regarding HRCT patterns.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12931-020-01562-2.

Acknowledgements

We express our gratitude to Minkyu Han in the Department of Clinical Epidemiology and Biostatistics, Asan Medical Centre, for valuable advice regarding the statistical analysis.
This study was approved by the Institutional Review Board of Asan Medical Centre (2018-1284).
Not applicable.

Competing interests

The authors declare that they have no conflicts of interest related to this study.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRef Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRef
2.
Zurück zum Zitat Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.CrossRef Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.CrossRef
3.
Zurück zum Zitat Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–42.CrossRef Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–42.CrossRef
4.
Zurück zum Zitat Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–90.CrossRef Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–90.CrossRef
5.
Zurück zum Zitat Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639–44.CrossRef Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639–44.CrossRef
6.
Zurück zum Zitat Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, et al. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med. 2017;131:229–35.CrossRef Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, et al. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med. 2017;131:229–35.CrossRef
7.
Zurück zum Zitat Arcadu A, Byrne SC, Pirina P, Hartman TE, Bartholmai BJ, Moua T. Correlation of pulmonary function and usual interstitial pneumonia computed tomography patterns in idiopathic pulmonary fibrosis. Respir Med. 2017;129:152–7.CrossRef Arcadu A, Byrne SC, Pirina P, Hartman TE, Bartholmai BJ, Moua T. Correlation of pulmonary function and usual interstitial pneumonia computed tomography patterns in idiopathic pulmonary fibrosis. Respir Med. 2017;129:152–7.CrossRef
8.
Zurück zum Zitat Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.CrossRef Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.CrossRef
9.
Zurück zum Zitat Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017;72:424–9.CrossRef Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017;72:424–9.CrossRef
10.
Zurück zum Zitat Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35.CrossRef Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35.CrossRef
11.
Zurück zum Zitat Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRef Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRef
12.
Zurück zum Zitat Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511–22.CrossRef Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511–22.CrossRef
13.
Zurück zum Zitat Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–46.CrossRef Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–46.CrossRef
14.
Zurück zum Zitat Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–75.CrossRef Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–75.CrossRef
15.
Zurück zum Zitat Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. Hoboken: Wiley; 2013. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. Hoboken: Wiley; 2013.
16.
Zurück zum Zitat Chung JH, Chawla A, Peljto AL, Cool CD, Groshong SD, Talbert JL, McKean DF, Brown KK, Fingerlin TE, Schwarz MI, et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest. 2015;147:450–9.CrossRef Chung JH, Chawla A, Peljto AL, Cool CD, Groshong SD, Talbert JL, McKean DF, Brown KK, Fingerlin TE, Schwarz MI, et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest. 2015;147:450–9.CrossRef
17.
Zurück zum Zitat Lee JW, Shehu E, Gjonbrataj J, Bahn YE, Rho BH, Lee MY, Choi WI. Clinical findings and outcomes in patients with possible usual interstitial pneumonia. Respir Med. 2015;109:510–6.CrossRef Lee JW, Shehu E, Gjonbrataj J, Bahn YE, Rho BH, Lee MY, Choi WI. Clinical findings and outcomes in patients with possible usual interstitial pneumonia. Respir Med. 2015;109:510–6.CrossRef
18.
Zurück zum Zitat Fukihara J, Kondoh Y, Brown KK, Kimura T, Kataoka K, Matsuda T, Yamano Y, Suzuki A, Furukawa T, Sumikawa H, et al. Probable UIP pattern on chest CT: Is it sufficient for a diagnosis of IPF? Eur Respir J. 2020;55:1802465.CrossRef Fukihara J, Kondoh Y, Brown KK, Kimura T, Kataoka K, Matsuda T, Yamano Y, Suzuki A, Furukawa T, Sumikawa H, et al. Probable UIP pattern on chest CT: Is it sufficient for a diagnosis of IPF? Eur Respir J. 2020;55:1802465.CrossRef
19.
Zurück zum Zitat Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138–53.CrossRef Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138–53.CrossRef
20.
Zurück zum Zitat Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017;195:78–85.CrossRef Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017;195:78–85.CrossRef
21.
Zurück zum Zitat Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med. 2018;18:19.CrossRef Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med. 2018;18:19.CrossRef
22.
Zurück zum Zitat Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340–6.CrossRef Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340–6.CrossRef
23.
Zurück zum Zitat Cocconcelli E, Balestro E, Biondini D, Barbiero G, Polverosi R, Calabrese F, Pezzuto F, Lacedonia D, Rea F, Schiavon M, et al. High-resolution computed tomography (HRCT) reflects disease progression in patients with idiopathic pulmonary fibrosis (IPF): relationship with lung pathology. J Clin Med. 2019;8:399.CrossRef Cocconcelli E, Balestro E, Biondini D, Barbiero G, Polverosi R, Calabrese F, Pezzuto F, Lacedonia D, Rea F, Schiavon M, et al. High-resolution computed tomography (HRCT) reflects disease progression in patients with idiopathic pulmonary fibrosis (IPF): relationship with lung pathology. J Clin Med. 2019;8:399.CrossRef
24.
25.
Zurück zum Zitat Kawasaki H, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2002;81:33–7.CrossRef Kawasaki H, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2002;81:33–7.CrossRef
26.
Zurück zum Zitat Kishi K, Homma S, Kurosaki A, Motoi N, Yoshimura K. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr. 2006;30:95–9.CrossRef Kishi K, Homma S, Kurosaki A, Motoi N, Yoshimura K. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr. 2006;30:95–9.CrossRef
27.
Zurück zum Zitat Caliò A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, Tomassetti S, Piciucchi S, Nottegar A, Rossi G, et al. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. Histopathology. 2017;71:725–35.CrossRef Caliò A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, Tomassetti S, Piciucchi S, Nottegar A, Rossi G, et al. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. Histopathology. 2017;71:725–35.CrossRef
28.
Zurück zum Zitat Chung JH, Oldham JM, Montner SM, Vij R, Adegunsoye A, Husain AN, Noth I, Lynch DA, Strek ME. CT-pathologic correlation of major types of pulmonary fibrosis: insights for revisions to current guidelines. Am J Roentgenol. 2018;210:1034–41.CrossRef Chung JH, Oldham JM, Montner SM, Vij R, Adegunsoye A, Husain AN, Noth I, Lynch DA, Strek ME. CT-pathologic correlation of major types of pulmonary fibrosis: insights for revisions to current guidelines. Am J Roentgenol. 2018;210:1034–41.CrossRef
29.
Zurück zum Zitat Widell J, Lidén M. Interobserver variability in high-resolution CT of the lungs. Eur J Radiol Open. 2020;7:100228–100228.CrossRef Widell J, Lidén M. Interobserver variability in high-resolution CT of the lungs. Eur J Radiol Open. 2020;7:100228–100228.CrossRef
30.
Zurück zum Zitat Bennett D, Mazzei MA, Collins B, Bargagli E, Pipavath S, Spina D, Valentini ML, Rinaldi C, Bettini G, Ginori A, et al. Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPF database”—a new software. Respir Med. 2019;147:31–6.CrossRef Bennett D, Mazzei MA, Collins B, Bargagli E, Pipavath S, Spina D, Valentini ML, Rinaldi C, Bettini G, Ginori A, et al. Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPF database”—a new software. Respir Med. 2019;147:31–6.CrossRef
Metadaten
Titel
Computed tomography patterns predict clinical course of idiopathic pulmonary fibrosis
verfasst von
Byoung Soo Kwon
Jooae Choe
Kyung Hyun Do
Hee Sang Hwang
Eun Jin Chae
Jin Woo Song
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Respiratory Research / Ausgabe 1/2020
Elektronische ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01562-2

Weitere Artikel der Ausgabe 1/2020

Respiratory Research 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.